Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer

Dear Colleagues,

Biomarkers play an essential role in the early detection, prognosis, and prediction of treatment response in cancer. Biomarkers are based on qualitative and/or quantitative assessment of biomolecules, such as DNA, RNA, and proteins. Biomarker detection can be performed on a variety of tissue samples, including tumor tissue derived from biopsies or surgical specimens, as well as less invasive samples such as blood, cervical Pap smears, and vaginal secretions, among others. 

In gynecologic cancers—including cancers of the uterine corpus, uterine cervix, fallopian tube, ovary, vagina, and vulva—biomarkers have increased in clinical relevance in recent years. For instance, molecular testing for high-risk subtypes of human papilloma virus (HPV) has transformed cervical cancer screening, while testing for HER2 expression has recently increased therapy options for some patients with endometrial serous carcinoma.

This Special Issue of Cancers encompasses new research articles and up-to-date reviews on all aspects of biomarkers and their relationship to treatment prediction, prognosis, and early detection of gynecologic cancer. Special attention will be given to submissions with clinical relevance.

Dr. Brian S Finkelman
Dr. Rachelle P Mendoza
Dr. Hani Katerji
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.